Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
A legfontosabb adatok
- Ki végzi
- Memorial Sloan Kettering Cancer Center
- Hol
- Allentown, Basking Ridge, Commack, Harrison, Miami, Middletown és New York (Egyesült Államok)Mind a 7 helyszín megnézése
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 30 fő vett részt
- Kezdés
- 2015. ápr. 22.
- Várható befejezés
- 2027. ápr.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Meclofenamate
- A regiszteradat frissítve
- 2026. május 29.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18-80
- KPS ≥ 60
- At least one recurrent or progressive brain metastasis (es) from any solid primary tumor that is visible on MRI as assessed by the patient's treating physician
- Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable
- There is no limit on the number of brain metastases
- Surgical resection or SRS to other recurrent lesions in the same patient are acceptable, provided one recurrent lesion remains untreated
- Systemic disease must be well-controlled or NED in the opinion of the patient's primary oncologist
Ki nem vehet részt
- Surgery less than two weeks before enrollment
- Concurrent anti-coagulation therapy
- Steroid dose increased in the most recent two weeks
- Progressive systemic disease
- Active Intracranial Hemorrhage
- GI hemorrhage (active or in recent 6 months)
- Active bleeding diathesis
- Allergy to meclofenamate or other NSAID
- Cardiac Arrhythmia requiring medical management and/or pacemaker
- Known congestive heart failure requiring medical management
- Concurrent anti-platelet therapy
- Platelet count ≤ 70,000/mm3
- International normalized ratio (INR) > 1.6 and a Partial Thromboplastin Time (PTT) > 40 seconds
- Serum Creatinine >2 mg/dL OR CrCL <30ml/min
- AST or ALT > 200 U/L
- Hemoglobin <8 g/dL
- Inability to get brain MRI +/- contrast
- Known leptomeningeal metastases
- Primary Brain tumor
- Inability to tolerate PO dosing
- Pregnancy
Helyszínek itt: Egyesült Államok
- Lehigh Valley Health NetworkAllentown, Egyesült Államok
- Memorial Sloan Kettering Cancer CenterBasking Ridge, Egyesült Államok
- Memorial Sloan Kettering Cancer Center at CommackCommack, Egyesült Államok
- Memorial Sloan Kettering WestchesterHarrison, Egyesült Államok
- Baptist Health South FloridaMiami, Egyesült Államok
- Memorial Sloan Kettering MonmouthMiddletown, Egyesült Államok
- Memorial Sloan-Kettering Cancer CenterNew York, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasis. This is the first time that meclofenamate will be used in patients with brain metastasis.
A teljes eredeti leírásKevesebb
This is a pilot study which means that the purpose of this study is to determine if a larger clinical trial of meclofenamate is possible in patients with brain metastasis. This study also aims to find out what effects, good and/or bad meclofenamate has on the patient and the cancer that has spread to the brain. The investigators also want to learn more about potential effects that this drug may have in the digestive system.
A vizsgálat csoportja
- MeclofenamateA vizsgált kezelés
All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
- Publikációk
- Pleiotropic Effects of the NSAID Fenamates on Chloride Channels: Opportunity for Ion Channelopathies?Pharmacology research & perspectives, 2025
- A regiszteradat frissítve
- 2026. május 29.